Anti-TSLP nanobody and applications therefor
Anti-TSLP nanobodies effectively block TSLP signaling, addressing the lack of effective treatments for non-Th2 asthma by enhancing TSLP receptor interaction blockade and improving expression yields, offering a promising therapeutic option for severe asthma.
Patent Information
- Application Number
- JP2024146304
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-26
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-05-16
AI Technical Summary
Current treatments for severe asthma that do not follow the Th2 inflammatory pathway are inadequate, and there is a need for new therapeutic pathways that can effectively target Thymic stromal lymphopoietin (TSLP) to manage non-Th2 type asthma.
Development of anti-TSLP nanobodies with specific CDR regions and framework regions, capable of blocking the interaction between TSLP and its receptor TSLPR, which are easy to produce and have high clinical therapeutic effects.
The anti-TSLP nanobodies demonstrate superior blocking activity compared to existing antibodies, inhibiting TSLP signaling and reducing asthma symptoms, with high expression yields in Pichia pastoris and improved inhibitory effects on BaF3/TSLPR-IL7R cells.
Smart Images

Figure 2024167316000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the biomedical or biopharmaceutical technical field, and more specifically to anti-TSLP nanobodies and uses thereof. [Background technology]
[0002] In recent years, the treatment pathways for moderate and severe asthma have focused on attempts to suppress the response of Th2 cells. Antibody drugs for treating severe asthma often target IgE (omalizumab), IL5 (mepolizumab, reslizumab), IL5R (benralizumab), IL4R (dupilumab), etc. in the Th2 pathway. All of these drugs have good control effects on eosinophilic asthma, and all are treated by subcutaneous or intravenous injection. Approximately one-third of severe asthma patients do not have the characteristics of Th2 inflammatory pathway activation, and currently, patients who are unable to control such non-Th2 type diseases with the existing standard of care and treatment have no biological treatment option, so the development of new treatment pathways is desired.
[0003] Thymic stromal lymphopoietin (TSLP) is a short-chain cytokine with a four-helix bundle folding structure that belongs to the IL-2 cytokine family. TSLP is an epithelial cytokine produced in response to proinflammatory stimuli (e.g., allergens, viruses, and other pathogens in the lungs) and plays an important role in the development and maintenance of airway inflammation. TSLP downstream drives the release of Th2 cytokines, including IL-4, IL-5, and IL-13, leading to inflammation and asthma symptoms. TSLP also inhibits the expression of many types of cells involved in non-Th2 inflammation. TSLP can also activate the inflammatory cascade, making it a potential target for a broad range of asthma patients. Blocking TSLP can prevent asthma exacerbations, improve asthma control, and address related conditions such as chronic obstructive pulmonary disease by preventing immune cell release of inflammatory cytokines.
[0004] Nanobodies (Nb), i.e., heavy chain nanoantibodies VHH (variable domain of heavy chain of heavy-chain antibody), are composed of a single heavy chain variable domain obtained by cloning the variable domain of a natural light chain-deficient heavy chain antibody (HCAb) present in camels. Nanobodies are the smallest unit currently available that is stable, fully functional, and capable of binding to antigens. Nanobodies have the characteristics of high stability, good water solubility, easy humanization, high targeting, and strong permeability, and are useful in immune experiments, diagnosis, and treatment. Nanoantibodies are gradually becoming the new generation of antibody therapy. Therefore, there is a strong need in the field to develop anti-TSLP nanobodies that have good blocking activity, good clinical therapeutic effects, and are easy to produce. Summary of the Invention [Problem to be solved by the invention]
[0005] The objective of the present invention is to provide an anti-TSLP nanobody that has good blocking activity, good clinical therapeutic effect, and is easy to produce. [Means for solving the problem]
[0006] In a first aspect of the present invention, there is provided an anti-TSLP Nanobody, wherein the CDR regions, which are the complementarity determining regions of the VHH chain in said Nanobody, are one or more selected from the group consisting of: (1) CDR1 represented by SEQ ID NO:1, CDR2 represented by SEQ ID NO:2, and CDR3 represented by SEQ ID NO:3; (2) CDR1 as set forth in SEQ ID NO: 14, CDR2 as set forth in SEQ ID NO: 15, and CDR3 as set forth in SEQ ID NO: 16; and (3) CDR1 represented by sequence number 27, CDR2 represented by sequence number 28, and CDR3 represented by sequence number 29. In another preferred embodiment, said CDR1, CDR2 and CDR3 are separated by the framework regions FR1, FR2, FR3 and FR4 of the VHH chain.
[0007] In another preferred embodiment, the VHH chain further comprises a framework region FR, the framework region FR being one or more selected from the following group: (1) FR1 represented by SEQ ID NO: 4, FR2 represented by SEQ ID NO: 5, FR3 represented by SEQ ID NO: 6, and FR4 represented by SEQ ID NO: 7; (2) FR1 represented by SEQ ID NO: 10: FR2 represented by SEQ ID NO: 5, FR3 represented by SEQ ID NO: 6, and FR4 represented by SEQ ID NO: 11; (3) FR1 represented by SEQ ID NO: 17: FR2 represented by SEQ ID NO: 18, FR3 represented by SEQ ID NO: 19, and FR4 represented by SEQ ID NO: 20; (4) FR1 represented by SEQ ID NO: 23, FR2 represented by SEQ ID NO: 18, FR3 represented by SEQ ID NO: 19, and FR4 represented by SEQ ID NO: 24; (5) FR1 as set forth in SEQ ID NO: 30, FR2 as set forth in SEQ ID NO: 31, FR3 as set forth in SEQ ID NO: 32, and FR4 as set forth in SEQ ID NO: 33; and (6) FR1 represented by SEQ ID NO: 36, FR2 represented by SEQ ID NO: 31, FR3 represented by SEQ ID NO: 32, and FR4 represented by SEQ ID NO: 37.
[0008] In another preferred embodiment, the CDR region of the VHH chain of said Nanobody comprises an amino acid sequence having at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 99% sequence identity to any of SEQ ID NOs: 1-3, 14-16, 27-29.
[0009] In another preferred embodiment, the amino acid sequence of the CDR region of the VHH chain of said Nanobody comprises one or more amino acid substitutions, preferably conservative amino acid substitutions, compared to any of SEQ ID NOs: 1-3, 14-16 and 27-29.
[0010] In another preferred example, any one of the above amino acid sequences further includes a derived sequence that has optionally undergone addition, deletion, modification and / or substitution of at least one amino acid (e.g., 1 to 3, preferably 1 to 2, more preferably 1) and that maintains the ability to specifically bind to TSLP.
[0011] In another preferred embodiment, the Nanobody is capable of specifically binding to TSLP.
[0012] In another preferred embodiment, the Nanobody is capable of effectively blocking the interaction of TSLP with TSLPR.
[0013] In another preferred embodiment, the TSLP is human or non-human mammalian TSLP.
[0014] In another preferred embodiment, the TSLP is human, mouse, rat, or non-human primate (eg, monkey) TSLP.
[0015] In another preferred embodiment, said Nanobodies include humanized antibodies, camelid-derived antibodies and chimeric antibodies.
[0016] In another preferred embodiment, the amino acid sequence of the VHH chain of said Nanobody is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34, SEQ ID NO:38, or a combination thereof6.
[0017] In another preferred embodiment, the anti-TSLP Nanobody comprises a monomer, a dimer (a bivalent antibody), a tetramer (a tetravalent antibody), and / or a multimer (a multivalent antibody).
[0018] In another preferred embodiment, the anti-TSLP Nanobody comprises a VHH chain having the amino acid sequence as set forth in one or more of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34 or SEQ ID NO:38.
[0019] In another preferred embodiment, the anti-TSLP Nanobody comprises a VHH chain having the amino acid sequence as set forth in two or more of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34, SEQ ID NO:38.
[0020] In another preferred embodiment, the VHH chains are linked via a linking peptide.
[0021] In another preferred embodiment, the connecting peptide is selected from the following sequences: a S b ) x (wherein a, b, x=0 or 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (preferably, a=4 and b=1, and x=4)).
[0022] In another preferred embodiment, the connecting peptide has the sequence GGGGSGGGGSGGGGSGGGGS.
[0023] In a second aspect of the invention, there is provided an anti-TSLP antibody, which is directed against a TSLP epitope, comprising an anti-TSLP nanobody according to the first aspect of the invention.
[0024] In another preferred embodiment, the anti-TSLP antibody comprises one or more anti-TSLP nanobodies.
[0025] In another preferred embodiment, the anti-TSLP antibody comprises a monomer, a dimer (bivalent antibody), a tetramer (tetravalent antibody), and / or a multimer (multivalent antibody).
[0026] In another preferred embodiment, the anti-TSLP antibody comprises a VHH chain having one or more of the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34, or SEQ ID NO:38.
[0027] In another preferred embodiment, the anti-TSLP antibody comprises two VHH chains having the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34, or SEQ ID NO:38.
[0028] In another preferred embodiment, the antibody is capable of specifically binding to TSLP.
[0029] In another preferred embodiment, the antibody is directed specifically against a TSLP protein having a precise spatial structure.
[0030] In another preferred embodiment, the antibody can effectively block the interaction of TSLP with TSLPR.
[0031] In another preferred embodiment, the affinity (KD value) of the antibody for TSLP is less than 3.77 nM.
[0032] In another preferred embodiment, the target antibody has excellent TSLP / TSLPR blocking activity and the blocking activity is significantly better than that of the control antibody Tezepelumab, where the control antibody Tezepelumab is available from AstraZeneca or Amgen.
[0033] In another preferred embodiment, the antibody can effectively inhibit the proliferation of BaF3 / TSLPR-IL7R cells, and its inhibitory activity is better than that of the control antibody tezepelumab.
[0034] In another preferred embodiment, the antibody is a nanobody.
[0035] In a third aspect of the invention, there is provided a polynucleotide encoding a protein selected from the group consisting of an anti-TSLP nanobody according to the first aspect of the invention or an anti-TSLP antibody according to the second aspect of the invention.
[0036] In another preferred embodiment, the polynucleotides are in a combinatorial form.
[0037] In another preferred embodiment, the polynucleotide comprises one or more of the sequences set forth in SEQ ID NO: 9, 13, 22, 26, 35 or 39.
[0038] In another preferred embodiment, the polynucleotide comprises RNA, DNA or cDNA.
[0039] In a fourth aspect of the invention there is provided an expression vector comprising a polynucleotide according to the third aspect of the invention.
[0040] In another preferred embodiment, the expression vector is selected from the group consisting of DNA, RNA, viral vectors, plasmids, transposons, other gene transfer systems, or combinations thereof.
[0041] In another preferred embodiment, the expression vector comprises a viral vector, such as a lentivirus, adenovirus, AAV virus, or retrovirus.
[0042] In a fifth aspect of the invention there is provided a host cell which comprises an expression vector according to the fourth aspect of the invention or has incorporated into its genome a polynucleotide according to the third aspect of the invention.
[0043] In another preferred embodiment, the host cell comprises a prokaryotic or eukaryotic cell.
[0044] In another preferred embodiment, the host cell is selected from the group consisting of E. coli, yeast cells, mammalian cells, phages, or combinations thereof.
[0045] In another preferred embodiment, the prokaryotic cell is selected from the group consisting of Escherichia coli, Bacillus subtilis, Lactobacillus acidophilus, Streptomyces, Proteus mirabilis, or a combination thereof.
[0046] In another preferred embodiment, the eukaryotic cell is selected from the group consisting of Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, or a combination thereof.
[0047] In another preferred embodiment, the host cell is Pichia pastoris.
[0048] In a sixth aspect of the invention, there is provided a method of producing an anti-TSLP Nanobody, the method comprising the steps of: (a) obtaining a culture comprising an anti-TSLP Nanobody by culturing a host cell according to the fifth aspect of the invention under conditions suitable for the production of said Nanobody; (b) isolating or recovering said anti-TSLP nanobody from said culture; and (c) Optionally, the anti-TSLP Nanobody obtained in step (b) is purified and / or modified.
[0049] In a seventh aspect of the present invention there is provided an immunoconjugate comprising: (a) an anti-TSLP nanobody according to the first aspect of the invention, or an anti-TSLP antibody according to the second aspect of the invention; and (b) a conjugate moiety selected from the group consisting of a detectable marker, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a gold nanoparticle / nanorod, a magnetic nanoparticle, a viral coat protein or VLP, or a combination thereof.
[0050] In another preferred embodiment, the radionuclide comprises: (i) a diagnostic isotope selected from the group consisting of Tc-99m, Ga-68, F-18, I-123, I-125, I-131, In-111, Ga-67, Cu-64, Zr-89, C-11, Lu-177, Re-188, or a combination thereof; and / or (ii) a therapeutic isotope selected from the group consisting of Lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd-103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Xe-133, Yb-169, Yb-177, or a combination thereof.
[0051] In another preferred embodiment, the conjugated moiety is a drug or a toxin.
[0052] In another preferred embodiment, the drug is a cytotoxic drug.
[0053] In another preferred embodiment, the cytotoxic drug is selected from the group consisting of antitubulin drugs, DNA minor groove binding agents, DNA replication inhibitors, alkylating agents, antibiotics, antifolates, antimetabolites, chemotherapy sensitizers, topoisomerase inhibitors, vinca alkaloids, or combinations thereof.
[0054] In another preferred embodiment, examples of particularly useful cytotoxic drugs include, for example, DNA minor groove binding agents, DNA alkylating agents, and tubulin inhibitors, and typical cytotoxic drugs include, for example, auristatins, camptothecins, duocarmycins, etoposide, maytansines and maytansinoids (e.g., DM1 and DM4), taxanes, benzodiazepines, or benzodiazepine-containing drugs. (benzodiazepine containing drugs) (e.g. pyrrolo[1,4]benzodiazepines (PBDs), indolinobenzodiazepines, and oxazolidinobenzodiazepines) and vinca alkaloids, or combinations thereof.
[0055] In another preferred embodiment, the toxin is auristatins (e.g., auristatin E, auristatin F, MMAE, and MMAF), chlortetracycline, maytansinoids, ricin, ricin A-chain, combretastatins, duocarmycins, dolastatins, adriamycin, daunorubicin, taxol, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, tenoposide, The toxin is selected from the group consisting of vincristine, vinblastine, colchicine, dihydroxyanthracenedione, actinomycin, diphtheria toxin, Pseudomonas aeruginosa exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-octastaphylococcus, gelonin, mitogellin, restrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, Sapaonaria officinalis inhibitor, glucocorticoids, or combinations thereof.
[0056] In another preferred embodiment, the conjugated moiety is a detectable marker.
[0057] In another preferred embodiment, the conjugated moiety is a fluorescent or luminescent marker, a radioactive marker, an MRI (magnetic resonance imaging) or CT (computed tomography) contrast agent, or an enzyme that produces a detectable product, a radionuclide, a biotoxin, a cytokine (such as IL-2), an antibody, an antibody Fc fragment, an antibody scFv fragment, a gold nanoparticle / nanorod, a virus particle, a liposome, a magnetic nanoparticle, a prodrug activating enzyme (such as DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL), or The nanoparticles are selected from the group consisting of nanoparticles in any form.
[0058] In an eighth aspect of the invention, there is provided a multispecific antibody comprising an anti-TSLP nanobody according to the first aspect of the invention, or an anti-TSLP antibody according to the second aspect of the invention.
[0059] In another preferred embodiment, the multispecific antibody further comprises an Fc fragment of an antibody.
[0060] In a ninth aspect of the present invention there is provided a recombinant protein comprising: (i) an anti-TSLP nanobody according to the first aspect of the invention, or an anti-TSLP antibody according to the second aspect of the invention; and (ii) An optional tag sequence to aid in expression and / or purification.
[0061] In another preferred embodiment, the tag sequences include an Fc tag, an HA tag and a 6His tag.
[0062] In another preferred embodiment, the recombinant protein specifically binds to the TSLP protein.
[0063] In a tenth aspect of the present invention, there is provided a pharmaceutical composition comprising: (i) an anti-TSLP nanobody according to the first aspect of the invention, or an anti-TSLP antibody according to the second aspect of the invention, or an immune complex according to the seventh aspect of the invention, or a multispecific antibody according to the eighth aspect of the invention, or a recombinant protein according to the ninth aspect of the invention; and (ii) A pharma- ceutically acceptable carrier.
[0064] In another preferred embodiment, the conjugated moiety of the immunoconjugate is a drug, a toxin, and / or a therapeutic isotope.
[0065] In another preferred embodiment, the pharmaceutical composition further comprises a drug for treating other immune system diseases or tumor diseases.
[0066] In another preferred embodiment, the drug for treating other immune system diseases or tumor diseases is selected from the group consisting of budesonide, fluticasone, beclomethasone, mometasone furoate, albuterol, theophylline, formoterol, tiotropium bromide, sulfasalazine, methotrexate, cyclophosphamide, fluorouracil, bleomycin, anastrozole, or a combination thereof.
[0067] In another preferred embodiment, the pharmaceutical composition is for use in the manufacture of a medicament for preventing and / or treating a disease or condition associated with TSLP.
[0068] In another preferred embodiment, the TSLP-associated disease or condition comprises an immune system disease or a tumor disease.
[0069] In another preferred embodiment, the immune system disease is selected from the group consisting of asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), allergic conjunctivitis, food allergy, ulcerative colitis, Crohn's disease, rhinitis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, allergic pneumonia, allergic granulomatous vasculitis, nasal polyps, or a combination thereof.
[0070] In another preferred embodiment, the tumor disease is selected from the group consisting of breast cancer, pancreatic adenocarcinoma, cervical cancer, multiple myeloma, colorectal cancer, lung cancer, thyroid cancer, ovarian cancer, liver cancer, or a combination thereof.
[0071] In an eleventh aspect of the invention, there is provided the use of an anti-TSLP nanoantibody according to the first aspect of the invention, an anti-TSLP antibody according to the second aspect of the invention, an immune complex according to the seventh aspect of the invention, or a multispecific antibody according to the eighth aspect of the invention, or a recombinant protein according to the ninth aspect of the invention, or a pharmaceutical composition according to the tenth aspect of the invention, (a) for the manufacture of a medicament for preventing and / or treating a disease associated with TSLP, and / or (b) for the manufacture of a reagent, detection plate or kit for detecting TSLP.
[0072] In another preferred embodiment, the TSLP-associated disease or condition comprises an immune system disease or a tumor disease.
[0073] In another preferred embodiment, the immune system disease is selected from the group consisting of asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), allergic conjunctivitis, food allergy, ulcerative colitis, Crohn's disease, rhinitis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, allergic pneumonia, allergic granulomatous vasculitis, nasal polyps, or a combination thereof.
[0074] In another preferred embodiment, the tumor disease is selected from the group consisting of breast cancer, pancreatic adenocarcinoma, cervical cancer, multiple myeloma, colorectal cancer, lung cancer, thyroid cancer, ovarian cancer, liver cancer, or a combination thereof.
[0075] In another preferred embodiment, the TSLP is human TSLP.
[0076] In another preferred embodiment, the reagent is a diagnostic reagent.
[0077] In another preferred embodiment, the diagnostic agent is a contrast agent.
[0078] In another preferred embodiment, the reagent is for detecting a TSLP protein or a fragment thereof in a sample.
[0079] In another preferred embodiment, the detection includes detection by flow cytometry, detection by cellular immunofluorescence.
[0080] In another preferred embodiment, the use is diagnostic and / or non-diagnostic, and / or therapeutic and / or non-therapeutic.
[0081] In a twelfth aspect of the invention, there is provided a method for detecting TSLP protein in a sample, the method comprising the steps of: (1) contacting a sample with an anti-TSLP nanoantibody according to the first aspect of the invention, or an anti-TSLP antibody according to the second aspect of the invention, or an immunoconjugate according to the seventh aspect of the invention, or a multispecific antibody according to the eighth aspect of the invention, or a recombinant protein according to the ninth aspect of the invention; (2) detecting whether antigen-antibody complexes are formed, where the formation of a complex indicates the presence of TSLP protein in the sample;
[0082] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.
[0083] In a thirteenth aspect of the present invention, there is provided a detection reagent for a TSLP protein, the detection reagent comprising: (i) an anti-TSLP nanobody according to the first aspect of the invention, or an anti-TSLP antibody according to the second aspect of the invention, or an immune complex according to the seventh aspect of the invention, or a multispecific antibody according to the eighth aspect of the invention, or a recombinant protein according to the ninth aspect of the invention; and (ii) A metrologically acceptable carrier.
[0084] In another preferred embodiment, the conjugated moiety of the immunoconjugate is a diagnostic isotope.
[0085] In another preferred embodiment, the metrically acceptable carrier is a non-toxic, inert aqueous carrier medium.
[0086] In another preferred embodiment, the detection reagent is one or more reagents selected from the group consisting of an isotope tracer, a contrast agent, a flow cytometry detection reagent, a cellular immunofluorescence detection reagent, a magnetic nanoparticle, and an imaging agent.
[0087] In another preferred embodiment, the detection reagent is for in vivo detection.
[0088] In another preferred embodiment, the detection reagent is in the form of a liquid or powder (eg, an aqueous solution, an injection, a lyophilized powder, a tablet, a lozenge, an aerosol inhalant).
[0089] In a fourteenth aspect of the invention, there is provided a kit for detecting TSLP protein, comprising an immune complex according to the seventh aspect of the invention or a detection reagent according to the thirteenth aspect of the invention, and instructions.
[0090] In another preferred embodiment, the instructions state that the kit is for non-invasively detecting TSLP expression in a subject.
[0091] In a fifteenth aspect of the invention, there is provided the use of an immunoconjugate according to the seventh aspect of the invention for the manufacture of an imaging agent for detecting TSLP protein in the body.
[0092] In another preferred embodiment, the detection is for the diagnosis or prognosis of a disease or condition associated with TSLP.
[0093] In a sixteenth aspect of the invention, there is provided a method of treating a disease comprising administering to a subject in need thereof an anti-TSLP nanoantibody according to the first aspect of the invention, an anti-TSLP antibody according to the second aspect of the invention, an immunoconjugate according to the seventh aspect of the invention, or a multispecific antibody according to the eighth aspect of the invention, or a recombinant protein according to the ninth aspect of the invention, or a pharmaceutical composition according to the tenth aspect of the invention.
[0094] In another preferred embodiment, the subject comprises a human or non-human mammal.
[0095] In another preferred embodiment, the non-human mammal includes rodents (eg, mice, rabbits) and non-human primates (eg, monkeys). Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. [Brief description of the drawings]
[0096] [Figure 1A] Figure 1A shows the results of flow cytometry detection of blocking activity of 31 candidate antibodies. The results show that the blocking activity of 14 of the 31 candidate antibodies was significantly better than that of the control antibody tezepelumab. [Figure 1B] Figure 1B shows the blocking activity of 31 candidate antibodies detected by flow cytometry. The results show that the blocking activity of 14 of the 31 candidate antibodies was significantly better than that of the control antibody tezepelumab. [Diagram 2] FIG. 2 shows the results of detecting the binding kinetics of 14 blocking TSLP nanoantibodies. [Diagram 3]Figure 3 shows the SDS-PAGE results of the expression supernatants of the bivalent single domain antibodies Bi-HuNb5-31, Bi-HuNb7-54, and Bi-HuNb10-63 expressed in shaking cultures in Pichia pastoris. The yields were 475ug / mL, 310ug / mL, and 510ug / mL, respectively. [Figure 4] Figure 4 shows the results of detecting the blocking activity of the humanized bivalent antibodies by ELISA. The results show that the blocking activity of the three humanized bivalent antibodies was significantly better than that of the control antibody tezepelumab. [Diagram 5] Figure 5 shows the results of the growth inhibitory effect of humanized bivalent antibodies on BaF3 / TSLPR-IL7R cells. The results show that the inhibitory effect of two of the humanized antibodies on the pSTAT5 signal pathway in BaF3 / TSLPR-IL7R cells was better than that of the control antibody tezepelumab. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0097] For the first time, an anti-TSLP nanobody has been unexpectedly found, and the experimental results show that the nanobody of the present invention can effectively block the interaction between TSLP and TSLPR, with a blocking activity significantly better than that of the control antibody tezepelumab, can effectively inhibit the proliferation of BaF3 / TSLPR-IL7R cells, with an inhibitory activity significantly better than that of the control antibody tezepelumab, and the yield of fermentation tank expression in Pichia pastoris reaches 17-23g / L, which is significantly higher than the industrial level. Based on this, the present inventor has completed the present invention.
[0098] term As used herein, the terms "Nanobody of the invention", "Nanobody of the invention", "anti-TSLP Nanobody of the invention", "TSLP Nanobody of the invention", "anti-TSLP Nanobody", and "TSLP Nanobody" have the same meaning and can be used interchangeably, and all refer to a Nanobody that specifically recognizes and binds to TSLP (including human TSLP).
[0099] As used herein, the term "antibody" or "immunoglobulin" refers to a heterotetrameric glycoprotein of approximately 150,000 daltons with similar structural characteristics, consisting of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds between the heavy chains depends on the immunoglobulin isotype. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end followed by multiple constant regions. Each light chain has a variable region (VL) at one end followed by a constant region at the other end. The constant region of the light chain faces the first constant region of the heavy chain, and the variable region of the light chain faces the variable region of the heavy chain. Special amino acid residues form an interface between the light and heavy chain variable regions.
[0100] As used herein, the terms "single domain", "VHH", "nanobody" and "heavy chain antibody" (sdAb or nanobody) have the same meaning and can be used interchangeably and refer to the variable region of the heavy chain of a cloned antibody, and a nanobody (VHH) consisting of only one heavy chain variable region is constructed and is the smallest fully functional antigen-binding fragment. Typically, an antibody lacking the natural light chain and heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the heavy chain of the antibody is further cloned to construct a nanobody (VHH) consisting of only one heavy chain variable region.
[0101] As used herein, the term "variable" refers to the fact that certain portions of the variable regions of antibodies differ in sequence, which constitutes the binding and specificity of each particular antibody to its particular antigen. However, variability is not uniformly distributed throughout the variable regions of antibodies. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions in the variable regions of the light and heavy chains. In the variable regions, the relatively conserved portions are called framework regions (FRs). Natural heavy and light chain variable regions each contain four FR regions that are essentially in a β-sheet structure, connected by three CDRs that form connecting loops, and sometimes in a partial β-sheet structure. The CDRs in each chain are in close contact with each other through the FR regions, and together with the CDRs of the other chain form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Vol. I, pp. 647-669 (1991)). The constant region is not directly involved in binding of an antibody to an antigen, but exhibits different effector functions, such as participating in antibody-dependent cellular toxicity of the antibody.
[0102] As will be known to those skilled in the art, immunoconjugates and fusion expression products include conjugates of the antibodies of the invention or fragments thereof conjugated to drugs, toxins, cytokines, radionuclides, enzymes, and other diagnostic or therapeutic molecules. Additionally, the invention includes cell surface markers or antigens conjugated to the anti-TSLP antibodies or fragments thereof.
[0103] As used herein, the terms "heavy chain variable region" and "VH" can be used interchangeably.
[0104] As used herein, the terms "variable region" and "complementarity determining region (CDR)" can be used interchangeably.
[0105] In one preferred embodiment of the invention, the heavy chain variable region of the antibody comprises three complementarity determining regions: CDR1, CDR2, and CDR3.
[0106] In one preferred embodiment of the invention, the heavy chain of the antibody comprises the above-described heavy chain variable region and heavy chain constant region.
[0107] In the present invention, the terms "antibody of the invention," "protein of the invention," or "polypeptide of the invention" are used interchangeably and all refer to a polypeptide that specifically binds to the TSLP protein, such as a protein or polypeptide having a heavy chain variable region, which may or may not contain an initial methionine.
[0108] The invention also provides other proteins or fusion expression products of the antibodies of the invention, specifically, the invention includes any protein or protein complex and fusion expression product (i.e., immunoconjugate and fusion expression product) having a heavy chain containing a variable region similar to or having at least 90%, preferably at least 95%, homology with the heavy chain variable region of an antibody of the invention.
[0109] In general, the antigen-binding properties of an antibody are characterized by three specific regions located in the heavy chain variable region, called the variable region (CDR), which are divided into four framework regions (FR), the amino acid sequences of which are relatively conserved and not directly involved in binding reactions. These CDRs form a ring structure, in which the FRs form a β-sheet that brings them into spatial proximity, and the CDRs in the heavy chain and the corresponding CDRs in the light chain constitute the antigen-binding site of the antibody. Comparison of the amino acid sequences of similar antibodies can identify which amino acids constitute the FR or CDR region.
[0110] The heavy chain variable region of the antibody of the present invention is of particular interest because at least a portion of it is involved in antigen binding. Therefore, molecules having a heavy chain variable region of a CDR-containing monoclonal antibody are included in the present invention as long as the CDRs have 90% or more (preferably 95% or more, most preferably 98% or more) homology with the CDRs identified herein.
[0111] The present invention includes not only complete antibodies, but also immunologically active antibody fragments or fusion proteins consisting of antibodies and other sequences, and therefore further includes fragments, derivatives and analogs of said antibodies.
[0112] As used herein, the terms "fragment," "derivative," and "analog" refer to a polypeptide that maintains essentially the same biological function or activity as an antibody of the invention. A fragment, derivative, or analog of a polypeptide of the invention may be (i) a polypeptide in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) have been substituted, whether or not such substituted amino acid residues are encoded by the genetic code, or (ii) a polypeptide in which one or more amino acid residues have been substituted, or (iii) a polypeptide in which the mature polypeptide is fused to another compound (e.g., a compound that extends the half-life of the polypeptide, such as polyethylene glycol), or (iv) a polypeptide in which an additional amino acid sequence has been fused to the polypeptide (e.g., a leader sequence, a secretory sequence, a sequence for purifying the polypeptide, a protein precursor sequence, or a fusion protein formed with a 6His tag). Based on the disclosure of the present specification, these fragments, derivatives, and analogs are within the scope of what is known to those of skill in the art.
[0113] The antibody of the present invention refers to a polypeptide having TSLP-binding activity and comprising the above-mentioned CDR region. The term further includes mutated forms of the polypeptide having the same function as the antibody of the present invention and comprising the above-mentioned CDR region. These mutated forms include, but are not limited to, deletion, insertion and / or substitution of one or more amino acids (usually 1 to 50, preferably 1 to 30, more preferably 1 to 20, most preferably 1 to 10) and addition of one or more amino acids (usually 20 or less, preferably 10 or less, more preferably 5 or less) to the C-terminus and / or N-terminus. For example, in this field, substitution with an amino acid having a close or similar function usually does not change the function of the protein. Furthermore, addition of one or more amino acids to the C-terminus and / or N-terminus usually does not change the function of the protein. The term further includes active fragments and active derivatives of the antibody of the present invention.
[0114] Variants of the polypeptide include homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA capable of hybridizing with the DNA encoding the antibody of the present invention under conditions of high or low stringency, and polypeptides or proteins obtainable with antisera against the antibody of the present invention.
[0115] The present invention further includes other polypeptides, such as fusion proteins of Nanobodies or fragments thereof. In addition to almost full-length polypeptides, the present invention further includes fragments of the Nanobodies of the present invention. Typically, said fragments comprise at least about 50 contiguous amino acids of an antibody of the present invention, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100 contiguous amino acids.
[0116] In the present invention, the term "conservative variants of the antibody of the present invention" refers to polypeptides in which, compared to the amino acid sequence of the antibody of the present invention, 10 or less, preferably 8 or less, more preferably 5 or less, and most preferably 3 or less amino acids have been substituted with amino acids having similar or close properties. These conservatively mutated polypeptides are preferably generated by substituting amino acids as shown in Table A.
[0117] [Table A]
[0118] Furthermore, the present invention provides a polynucleotide molecule encoding the above-mentioned antibody or a fragment thereof or a fusion protein thereof. The polynucleotide of the present invention may be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA may be single-stranded or double-stranded. The DNA may be the coding strand or the non-coding strand.
[0119] A polynucleotide encoding a mature polypeptide of the present invention includes a coding sequence encoding only the mature polypeptide, a coding sequence for the mature polypeptide and various additional coding sequences, a coding sequence for the mature polypeptide (and any additional coding sequences) and non-coding sequences.
[0120] The term "polynucleotide encoding a polypeptide" may be a polynucleotide that encodes the polypeptide, or it may further comprise additional coding and / or non-coding sequences.
[0121] The present invention further relates to polynucleotides that hybridize with the above sequences and have at least 50%, preferably at least 70%, more preferably at least 80% homology between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" are (1) low ionic strength and high temperature, such as 0.2xSSC, 0.1% SDS, hybridization and elution at 60°C, or (2) the inclusion of a denaturing agent during hybridization, such as 50% (v / v) formamide, 0.1% fetal bovine serum / 0.1% Ficoll at 42°C, or (3) hybridization only when the homology between the two sequences is at least 90% or more, preferably 95% or more. And the polypeptides encoded by the hybridizable polynucleotides have the same biological functions and activities as the mature polypeptides.
[0122] The full length nucleotide sequence or fragments of the antibody of the present invention are usually obtained by PCR amplification, recombinant techniques or artificial synthesis. Applicable methods include synthesis of related sequences by artificial synthesis, especially when the fragments are short in length. Usually, multiple small fragments are first synthesized and then concatenated to obtain a long fragment of the sequence. The coding sequence of the heavy chain may also be fused together with an expression tag (e.g., 6His) to form a fusion protein.
[0123] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant techniques, typically by cloning the sequence into a vector, introducing it into a cell, and isolating the relevant sequence from the host cell which has been grown in the usual manner. Biological molecules (nucleic acids, proteins, etc.) according to the present invention include biological molecules that exist in isolated form.
[0124] At present, it is already possible to obtain the DNA sequence encoding the protein of the present invention (or a fragment or derivative thereof) entirely by chemical synthesis. Furthermore, this DNA sequence may be introduced into various known DNA molecules (or vectors, etc.) or cells well known in the art. Mutations may also be introduced into the protein sequence of the present invention by chemical synthesis.
[0125] The present invention further relates to vectors containing the appropriate DNA sequences as described above and appropriate promoter or control sequences, which can be used to transform an appropriate host cell so as to express the protein.
[0126] The host cell may be a prokaryotic cell, such as a bacterial cell, or a lower eukaryotic cell, such as a yeast cell, or a higher eukaryotic cell, such as a mammalian cell, typically including bacterial cells such as E. coli, Streptomyces, Salmonella typhimurium, fungal cells such as yeast, insect cells such as fruit fly S2 or Sf9, and animal cells such as CHO, COS7, and 293 cells.
[0127] Transformation of host cells by DNA recombination may be performed by conventional techniques familiar to those skilled in the art. When the host is a prokaryotic cell, such as E. coli, competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the process used being well known in the art. Another method uses MgCl2. Optionally, transformation may be by electroporation. When the host is a eukaryotic organism, conventional mechanical methods such as calcium phosphate precipitation, microinjection, electroporation, and DNA transfection methods such as lipofection are used.
[0128] The obtained transformant can be cultured by a conventional method to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, a conventional medium may be selected as the medium for culture. The culture is performed under conditions suitable for the growth of the host cells. When the host cells have grown to an appropriate cell density, the selected promoter is induced by an appropriate method (e.g., temperature shift or chemical induction), and the cells are further cultured.
[0129] The recombinant polypeptide in the above method can be expressed intracellularly or in the cell membrane, or can be secreted extracellularly. If necessary, the recombinant protein can be isolated and purified by various isolation methods based on its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to, conventional renaturation, treatment with protein precipitants (salting out), centrifugation, osmotic shock, sonication, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques, as well as combinations of these methods.
[0130] The antibodies of the present invention may be used alone, or may be conjugated or coupled to a detectable marker (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modulating moiety, or any combination thereof.
[0131] Detectable markers used for diagnostic purposes include, but are not limited to, fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes that produce a detectable product.
[0132] Therapeutic agents that can be conjugated or complexed with the antibodies of the present invention include, but are not limited to, 1. radionuclides, 2. biotoxins, 3. cytokines, such as IL-2, 4. gold nanoparticles / nanorods, 5. viral particles, 6. liposomes, 7. magnetic nanoparticles, 8. prodrug activating enzymes (e.g., DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)), and the like.
[0133] Thymic stromal lymphopoietin (TSLP) Thymic stromal lymphopoietin is a short-chain cytokine with a four-helix bundle folding structure, belonging to the IL-2 cytokine family. As a new cytokine, TSLP is normally expressed in epithelial cells on the surface of the lung, skin, and intestinal barrier. Animal experiments have shown that TSLP is highly expressed in the lungs of allergen-induced model mice, while TSLP receptor-deficient mice exhibited obvious alleviation of asthma symptoms, and lung-specific TSLP transgenic mice exhibited Th2-type inflammation and tracheal inflammation with enhanced IgE, and were hyperresponsive. Further studies have shown that TSLP is expressed in bone marrow-derived TSLP-associated inflammatory cells. It has been suggested that TSLP activates dendritic cells and upregulates costimulatory molecules to produce the Th2-type chemokine CCL17. Therefore, TSLP is a prerequisite for the development of airway allergic inflammation. It is an upstream regulator of many inflammatory pathways in various diseases, including asthma, and is very important in the development and maintenance of airway inflammation. Furthermore, studies have shown that TSLP is also a cytokine involved in the pathogenesis of atopic dermatitis (AD). More importantly, researchers have already found that TSLP levels are increased in many different tumors, and that tumors can also be induced to express another protein called BCL-2, which protects the tumor from dying. Therefore, TSLP is also very important for tumor survival.
[0134] thymic stromal lymphopoietin receptor (TSLPR) The TSLPR receptor is a type I transmembrane protein that belongs to the hematopoietic cytokine receptor family. The functional TSLPR complex consists of TSLPR and IL-7Ra. TSLPR is also called cytokine receptor-like molecule 2 or type I cytokine receptor σ1. TSLP initiates intracellular type 2 signal transduction by binding to its high affinity heterodimeric receptor complex, which consists of its specific receptor TSLPR, which has 24% homology with the common receptor γ chain in IL-2, IL-4, IL-9 and IL-15, and does not contain the δ-common chain IL-2 family, and the IL-7Rα subunit (CD127) in cells that co-express TSLPR and IL-7Rα. TSLP first binds to TSLPR and further recruits the IL-7Rα chain.
[0135] Drug Compositions The present invention further provides a composition. Preferably, the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein and a pharma- ceutically acceptable carrier. Usually, these substances are formulated in a non-toxic, inert, pharma-ceutically acceptable aqueous carrier, and the pH value is usually about 5 to 8, preferably about 6 to 8, depending on the nature of the formulated substance and the disease to be treated. The formulated pharmaceutical composition can be administered by any usual route, including, but not limited to, intraperitoneal, intravenous, or topical administration.
[0136] The pharmaceutical composition of the present invention can be used to directly bind to the TSLP protein molecule, and is therefore useful for treating diseases or conditions associated with TSLP, including immune system diseases and tumor diseases, and may be used in combination with other therapeutic agents.
[0137] The pharmaceutical composition of the present invention contains a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above nanobody (or complex thereof) of the present invention and a pharma- ceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffer, glucose, water, glycerin, ethanol, and combinations thereof. The drug formulation corresponds to the mode of administration. The pharmaceutical composition of the present invention may be an injection, which can be prepared by a conventional method, for example, in physiological saline or an aqueous solution containing glucose and other auxiliaries. The pharmaceutical composition is prepared under sterile conditions in the case of an injection or solution. The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 μg / kg body weight to about 50 mg / kg body weight daily. The polypeptide of the present invention can also be used in combination with other therapeutic agents.
[0138] When using the pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to a mammal, and the safe and effective amount is usually at least about 10 μg / kg body weight, and in many cases, less than about 50 mg / kg body weight, and preferably the dosage is about 10 μg / kg body weight to about 10 mg / kg body weight. Of course, the specific dosage should further take into account factors such as the mode of administration and the health condition of the patient, all of which are within the skill of a skilled physician.
[0139] Anti-TSLP nanobody In the present invention, the amino acid sequence of the VHH chain of said anti-TSLP Nanobody is selected from one or more of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34 or SEQ ID NO:38.
[0140] In one preferred embodiment of the invention, the anti-TSLP Nanobody comprises a monomer, a dimer (bivalent antibody), a tetramer (tetravalent antibody), and / or a multimer (multivalent antibody).
[0141] Typically, said anti-TSLP Nanobody comprises two VHH chains having the amino acid sequences shown in SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34 or SEQ ID NO:38.
[0142] In another preferred embodiment, the VHH chains are linked via a linking peptide.
[0143] In another preferred embodiment, the connecting peptide is selected from the following sequences: a S b ) x (wherein a, b, x=0 or 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (preferably, a=4 and b=1, and x=4)).
[0144] In another preferred embodiment, the connecting peptide has the sequence GGGGSGGGGSGGGGSGGGGS.
[0145] Labeled nanoantibodies In one preferred embodiment of the invention, said Nanobody carries a detectable marker, more preferably said marker is selected from the group consisting of an isotope, a colloidal gold marker, a colored marker or a fluorescent marker. Colloidal gold markers may be performed by methods known to those skilled in the art. In one preferred embodiment of the invention, a nanobody of TSLP is labeled with colloidal gold to obtain a nanobody labeled with colloidal gold.
[0146] Detection Method The present invention also relates to methods for detecting TSLP protein, which essentially comprise the steps of obtaining a cell and / or tissue sample, lysing the sample in a medium, and detecting the level of TSLP protein in the lysed sample. In the detection method of the present invention, the sample used is not particularly limited, and a representative example is a sample containing cells present in a cell preservation solution.
[0147] kit The present invention also provides a kit containing the antibody (or fragment thereof) or cassette of the present invention, and in a preferred embodiment of the present invention, the kit further includes a container, instructions for use, buffer solutions, etc.
[0148] The present invention also provides a detection kit for detecting TSLP levels, which includes an antibody that recognizes the TSLP protein, a lysis medium for dissolving the sample, and general-purpose reagents and buffers required for detection, such as various buffers, detection markers, detection substrates, etc. The detection kit may be an in vitro diagnostic device.
[0149] application As described above, the Nanobody of the present invention has broad biological and clinical application value, and its applications cover many fields, including the diagnosis and treatment of diseases or conditions associated with TSLP, basic medical research, biological research, etc. One preferred application is for use in clinical diagnosis and targeted therapy of TSLP.
[0150] The main advantages of the present invention are: (a) The Nanobodies of the invention can effectively block the interaction between TSLP and TSLPR. (b) The Nanobodies of the invention have stronger blocking activity than the control antibody tezepelumab. (c) The nanobodies of the invention can be expressed in Pichia pastoris, with high expression yields in shake culture and fermentation tank yields reaching 17-23 g / L. (d) The nanobodies of the invention have a significantly better inhibitory effect on the pSTAT5 signaling pathway in BaF3 / TSLPR-IL7R cells than the control antibody tezepelumab.
[0151] The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. Experimental methods for which no specific conditions are given in the following examples are generally performed according to standard conditions, such as those described in Sambrook et al., "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommended conditions. Unless otherwise stated, percentages and parts are percentages and parts by weight. Unless otherwise stated, all materials or reagents used in the examples of the present invention are commercially available.
[0152] Example 1 Screening for TSLP-specific nanobodies The amino acid sequence of human TSLP with a mutated furin cleavage site was optimized according to human codons, and the base sequence was cloned into the pFUSE vector, transfected into HEK293F cells, and purified to obtain human TSLP protein. The highly purified protein was mixed with immune adjuvant, and four Xinjiang Bactrian camels were immunized once a week for a total of seven times. The peripheral blood of the camels was then collected, RNA was isolated, and VHH gene fragments were amplified. The fragments were then cloned into the pMECS vector and electrotransformed into TG1-sensitive cells to construct a high-quality phage-displayed nanoantibody library. Detection showed that all four libraries had a capacity of 1 × 10 9 Over CFU, the fragment insertion rate reached 80% or more.
[0153] Phage display technology was used to screen for TSLP-specific nanoantibodies. After three rounds of "adsorption-washing-assembly" processes, each library produced a collection of specific nanoantibody phages. From these, 1200 clones were selected for ELISA detection and sequencing, and finally 312 antibodies with different sequences were obtained.
[0154] Example 2 Screening of TSLP nanoantibody by flow cytometry The above nanoantibodies with different sequences were cloned and inoculated into TB medium, cultured and induced with IPTG overnight, the cells were lysed, and the supernatant was collected and used to detect blocking activity. The cultured CHOZEN / TSLPR stably transfected cells were divided and placed in a 96-well plate, with 3E5 cells per well, centrifuged at 3000 rpm for 3 min, the supernatant was discarded, and the lysate of each antibody and TSLP-biotin protein were added and incubated for 20 min. The supernatant was discarded after centrifugation, and the diluted SA-PE antibody was added and incubated at 4°C for 20 min. The supernatant was further discarded after centrifugation, and 200 μL of PBS-resuspended cells were added to each well, and the PE signal of the sample was detected by a flow cytometer. The results showed that a total of 64 candidate antibodies had the function of blocking the interaction between TSLP and TSLPR. In addition to sequencing, 31 different families of antibodies were selected and expressed and purified. For the purification method, please refer to Example 4 in Patent CN110144011A.
[0155] The above 31 purified antibodies were further subjected to blocking activity detection by flow cytometry. Cultured HEK293F / TSLPR transiently transfected cells were divided and placed in a 96-well plate, with 3E5 cells per well, centrifuged at 3000 rpm for 3 min, the supernatant was discarded, and gradient-diluted antibodies (diluted in a 2-fold gradient from 20 μg / mL) and TSLP-biotin protein were added and incubated for 20 min. In this experiment, tezepelumab was used as the control antibody. Then, the plate was centrifuged to discard the supernatant, and diluted SA-PE antibody was added and incubated at 4 °C for 20 min. The plate was further centrifuged to discard the supernatant, and 200 μL of PBS-resuspended cells were added to each well, and the PE signal of the sample was detected by flow cytometer. The results are shown in Figures 1A and 1B. Among them, the blocking activity of 14 antibodies was significantly better than that of the control antibody tezepelumab, and the numbers of the 14 antibodies are Nb1-41, Nb1-51, Nb1-59, Nb3-18, Nb3-43, Nb5-31, Nb6-29, Nb7-54, Nb10-55, Nb10-63, Nb10-87, Nb11-6, Nb11-72, and Nb11-75, respectively.
[0156] Example 3 Measurement of antibody affinity The binding kinetics of 14 blocking TSLP nanoantibodies was detected by Bio-layer interference technology (BLI). For the measurement of kinetics, the candidate antibodies were diluted to 5 μg / mL in PBST buffer, and the TSLP-Fc antigen was diluted to six concentrations in PBST buffer with a two-fold gradient (diluted from 20 nM with a two-fold gradient), and the operating conditions of the instrument were a temperature of 30 °C and a shake speed of 1000 rpm. The antibody was captured with a protein A-coated probe, and the capture time was 60 s, and it was bound to the gradient-diluted antigen, with an association time of 240 s and a dissociation time of 300 s, and it was regenerated twice with 10 mM glycine (pH 1.7), each time for 5 s. The data were analyzed by Fortebio Analysis version 9.0, and fitting was performed in Global mode to calculate the binding rate (Kon), dissociation rate (Kdis) and dissociation constant KD. The results are shown in Figure 2.
[0157] Example 4 Expression of a humanized bivalent antibody in Pichia pastoris The candidate antibody is subjected to humanization modification, the variable region is left as it is, and the sequence of the four framework regions is designed for humanization, and the modification method is referred to the method in Example 4 of Patent CN2018101517526. The amino acid sequence of the humanized antibody is shown in Table 1.
[0158] [Table 1]
[0159] The above humanized antibodies were constructed in a bivalent form and linked with a linker (G4S)4. The linked sequences are shown in SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42, and then expressed in Pichia pastoris. Schematically, the expression method is as follows: (1) The above TSLP nanoantibody dimer sequences were constructed in pPICZaA vector. (2) After linearization with Sac I restriction enzyme, they were electrically transfected into X-33 sensitive cells. (3) The electrically transfected samples were plated on bleomycin-resistant YPD plate media of different concentrations and cultured in an incubator at 30°C for 3-4 days. (4) After single clones were formed on the plate media, single clones on the plates of different concentrations were selected and placed in BMGY medium. When the OD value of BMGY medium reached about 20, the bacteria were collected and replaced with BMMY medium, and cultured at 28°C and 250 rpm. (5) After that, samples were taken every 24 hours, and methanol was added to the final volume of 1%. The samples were centrifuged at 12,000 rpm for 5 minutes, and the supernatant was taken and stored at -20°C. Induction was continued for 5 consecutive days, and the culture was terminated. (6) SDS-PAGE detection was performed on the obtained supernatant samples. The expression levels of the bivalent single domain antibody in the shaking culture are shown in Figure 3.
[0160] Example 5 Detection of blocking activity of humanized bivalent antibodies by ELISA Blocking activity was detected by ELISA for the above purified bivalent humanized antibodies. Human TSLP antigen protein was divided and placed in a 96-well plate and incubated overnight at 4°C. After washing five times with PBST, 300 μL of 1% BSA blocking solution was added and incubated at 37°C for 2 hours. After washing five times with PBST, 50 μL of gradient diluted antibody sample was added, and 50 μL of 0.02 μg / mL biotinylated TSLPR protein was added to each well and incubated at 37°C for 1 hour. After washing five times with PBST, 100 μL of SA-HRP (diluted at 1:100000) was added and incubated at 37°C for 1 hour. After washing five times with PBST, 100 μL of TMB coloring solution was added, coloring was performed at 37°C for 10 min, and 2M H2SO4 was added at 50 μL / well to stop the reaction, and the absorbance value was measured at a wavelength of 450 nm using a microplate reader. As shown in Figure 4, the blocking activity of the three humanized bivalent antibodies was significantly better than that of the control antibody tezepelumab.
[0161] Example 6 Inhibitory effect of humanized bivalent antibodies on the pSTAT5 signal pathway in BaF3 / TSLPR-IL7R cells Well-grown BaF3 / TSLPR-IL7R cells were centrifuged at 1000 rpm for 5 min, resuspended in PBS, and diluted to 1x10 5 The cells were divided into wells and placed in a 96-well plate. 25 μL of diluted human TSLP factor was mixed with gradient-diluted bivalent humanized antibody or tezepelumab, incubated at 37 degrees for 30 minutes, and then the mixture was placed in the cells and placed at 37 degrees Celsius and 5% CO2 for 20 minutes. After washing the cells with PBS, they were fixed with formaldehyde and further incubated with chilled formaldehyde for 10 minutes. Finally, anti-phosphorylated STAT5-PE-labeled antibody was added and incubated for 30 minutes, the cells were washed, and the PE signal value was detected by placing it in a flow cytometer. The results are shown in Figure 5, and the inhibitory effect of two of the humanized antibodies on the pSTAT5 signal pathway in BaF3 / TSLPR-IL7R cells was significantly better than that of the control antibody tezepelumab.
[0162] Example 7. Evaluation of yield of humanized bivalent antibody in 7 L fermentation tank The glycerol stocks of the above three antibody expression strains were amplified and cultured at 1:100 to obtain primary seeds, and then transferred to fresh medium for secondary seed culture. When the secondary seed culture passed, it was inoculated into a 7L fermentation tank for fermentation culture, and ammonia water was automatically added to adjust the pH of the fermentation culture to 6.0. During the culture process, the pH of the fermentation liquid, the wet weight of the bacteria, the OD value of the bacteria liquid, etc. were detected periodically, and the stirring speed, tank pressure, and oxygen introduction amount were adjusted according to the change in dissolved oxygen. According to the change in the wet weight of the fermentation bacteria and the dissolved oxygen, glycerol-supplemented medium and methanol-supplemented medium were respectively added at different stages of fermentation culture. The fermentation was induced with methanol and cultured for 160h to 200h, and fermentation was stopped. The yields of the above three humanized bivalent antibodies were detected to be 17g / L, 19g / L, and 23g / L, respectively. The yields of the antibodies far exceeded the fermentation expression yields of all types of antibodies already reported, reaching the top level in the industry.
[0163] Sequence information: SEQ ID NO:1: GFTLDDSDMG SEQ ID NO:2: ISLGGT SEQ ID NO:3: APGTDRYSDCPNEYSV SEQ ID NO:4: QVQLQESGGGSVQAGGSLRLSCTAS SEQ ID NO:5: WYRQAPGDECELVST SEQ ID NO:6: YYADSVKGRFTISHDNAKNTVYLQMNSLKPHDTAVYYC SEQ ID NO:7: WGQGTQVTVSS SEQ ID NO:8: QVQLQESGGGSVQAGGSLRLSCTASGFTLDDSDMGWYRQAPGDECELVSTISSLGGTYYADSVKGRFTISHDNAKNTVYLQMNSLKPHDTAVYYCAPGTDRYSDCPNEYSVWGQGTQVTVSS SEQ ID NO:9: CAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTACAGCCTCTGGATTCACTTTGGATGATTCTGACATGGGCTGGTACCGCCAGGCTCCAGGGGATGAGTGCGAGTTGGTCTCAACTATTAGTAGTTTGGGTGGCACATACTATGCAGAC TCCGTGAAGGGCCGATTCACCATCTCCCATGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAAACCTCACGACACGGCCGTGTATTACTGTGCGCGGGGACAGACCGTTATAGCGACTGCCCTAATGAGTATAGCGTCTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA SEQ ID NO:10: EVQLLESGGGLVQPGGSLRLSCTAS SEQ ID NO:11: WGQGTLVTVSS SEQ ID NO:12: EVQLLESGGGLVQPGGSLRLSCTASGFTLDDSDMGWYRQAPGDECELVSTISSLGGTYYADSVKGRFTISHDNAKNTVYLQMNSLKPHDTAVYYCAPGTDRYSDCPNEYSVWGQGTLVTVSS SEQ ID NO:13: GAGGTTCAATTGTTGGAATCTGGTGGTGGTTTGGTTCAACCAGGTGGTTCTTTGAGATTGTCTTGTACTGCTTCTGGTTTCACCTTGGACGATTCTGATATGGGATGGTACAGACAAGCTCCAGGAGATGAGTGTGAGTTGGTTTCTACTATCTCTTCCTTGGGTGGAACCTACTACGCTGAT TCTGTCAAGGGTCGTTTCACTATTTCTCACGATAATGCTAAGAACACCGTTTACTTGCAAATGAACTCTTTAAAGCCACATGATACTGCCGTTTACTACTGTGCTCCTGGTACTGATAGATACTCTGACTGTCCAAACGAATACTCCGTTTGGGGTCAGGGTACTTTGGTTACTGTCTCTTCC SEQ ID NO:14: GFTFDDSDMG SEQ ID NO:15: ISSDGMT SEQ ID NO:16: AATKYSSDYDVAEDWRRGVCGDMDY SEQ ID NO:17: QVQLQESGGGSVQAGETLRLSCTAS SEQ ID NO:18: WYRQAPGNECELVSI SEQ ID NO:19: YYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYYC SEQ ID NO:20: WGKGTQVTVSS SEQ ID NO:21: QVQLQESGGGSVQAGETLRLSCTASGTFDDDSDMGWYRQAPGNECELVSIISSDGMTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYYCAATKYSSDYDVAEDWRRGVCGDMDYWGKGTQVTVSS SEQ ID NO:22: CAGGTGCAGCTGCAGGAGTCTGGAGGAGGCTCGGTGCAGGCTGGAGAGACTCTGAGACTCTCCTGTACAGCCTCTGGATTCACTTTTGATGATTCTGACATGGGCTGGTACCGCCAGGCTCCAGGGAATGAGTGCGAGTTGGTCTCAATTATTAGTAGTGATGGTATGACACTACTATGCAGACTCCGTGAAGGGCC GATTCACCATCTCCCAAGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACAGCCGTGTATTACTGTGCGGCGACGAAGTACTCCAGCGACTATGACGTAGCTGAGGATTGGAGACGCGGGGTCTGTGGAGACATGGACTACTGGGGCAAAGGAACCCAGGTCACGTCTCCTCA sequence number 23: EVQLLESGGGLVQPGETLRLSCTAS sequence number 24: WGKGTLVTVSS sequence number 25: EVQLLESSGGGLVQPGETLRLSCTASGFTFDDSMGWYRQAPGNECELVSIISSDGMTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYCAATKYSSDYDVAEDWRRGVCGDMDYWGKGTLVTVSS sequence number 26: GAAGTCCAATTGCTTGAATCCGGTGGTGGATTAGTTCAACCAGGTGAGACCTTGAGACTGTCCTGTACCGCTTCCGGTTTCACTTTCGACGACTCCGACATGGGTTGGTACAGACAGGCTCCAGGTAATGAGTGTGAGTTGGTTTCTATTATTTCCTCTGATGGTATGACTTACTACGCTGATTCTGTTAAGGGTA GATTCACTATCTCTCAAGACAATGCTAAGAACACTGTTTACTTGCAAATGAACTCTTTGAAGCCTGAAGATACCGCCGTCTACTACTGTGCTGCCACCAAGTACTCCTCCGATTATGATGTCGCTGAAGATTGGAGAAGAGGAGTTTGTGGAGATATGGATTACTGGGGTAAAGGTACTTTGGTTACCGTTTCTTCT SEQ ID NO:27: GFTSGGSDMG SEQ ID NO:28: ISSDGST SEQ ID NO:29: AATDYGLGPPPSSTGQCYGMDY SEQ ID NO:30: QVQLQESGGGSVQAGGSLRLSCTAS SEQ ID NO:31: WYRQAPGNECDLVSY SEQ ID NO:32: YYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYYC SEQ ID NO:33: WGKGTQVTVSS SEQ ID NO:34: QVQLQESGGGSVQAGGSLRLSCTASGFTSGGSDMGWYRQAPGNECDLVSYISSDGSTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYYCAATDYGLGPPPSSTGQCYGMDYWGKGTQVTVSS SEQ ID NO:35: CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTACAGCCTCTGGATTCACTTCTGGCGGTTCTGACATGGGCTGGGTACCGCCAGGCTCCAGGGAATGAGTGCGACTTGGTTCCATATATTAGTAGTGATGGTAGCACATACTATGCAGACTCCGTGAAG GGCCGATTCACCATCTCCCAAGACAACGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACAGGGCCGTGTATTACTGTGCGGCCACCGACTATGGGTTGGGGCCGCCCCCTTCTTCGACGGGCCAATGTTACGGCATGGACTACTGGGGCAAAGGAACCCAGGTCACGTCTCCTCA sequence number 36: EVQLLESGGGLVQPGGSLRLSCTAS sequence number 37: WGKGTLVTVSS sequence number 38: EVQLLESSGGGLVQPGGSLRLSCTASGFTSGGSDMGWYRQAPGNECDLVSYISSDGSTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYCAATDYGLGPPSSTGQCYGMDYWGKGTLVTVSS sequence number 39: GAAGTTCAGTTGTTGGAATCAGGTGGTGGTTTGGTTCAACCAGGAGGTTCTCTGAGATTGTCTTGTACTGCTTCCGGTTTCACTTCCGGAGGTTCTGACATGGGATGGTACCGTCAAGCTCCTGGTAACGAGTGCGACTTGGTTTCTTACATCTCTTCCGACGGTTCCACTTACTACGCTGATTCTGTTAAG GGTAGATTCACTATTTCTCAAGACAACGCTAAGAATACTGTTTACTTGCAGATGAACTCTTTGAAGCCAGAGGATACCGCTGTTTACTATTGTCCCGCCACTGATTACGGTTTGGGTCCTCCACCATCTTCTACTGGACAATGTTACGGTATGGATTACTGGGGTAAAGGTACCCTGGTCACCGTTTCCTCT sequence number 40: EVQLLESSGGGLVQPGGSLRLSCTASGFTLDDSDMGWYRQAPGDECELVSTISSLGGTYYADSVKGRFTISHDNAKNTVYLQMNSLKPHDTAVYYCAPGTDRYSDCPNEYSVWGQGTLVTVSSGGGGGSGGGSGGGGSGGGGSEVQLLESSGGGLVQPGGSLRLSCTASGFTLDDSDMGWYRQAPGDECELVSTISSLGGTYYADSVKGRFTISHDNAKNTVYLQMNSLKPHDTAVYYCAPGTDRYSDCCPNEYSVWGQGTLVTVSS sequence number 41: EVQLLESSGGGLVQPGETLRLSCTASGFTFDDSMGWYRQAPGNECELVSIISSDGMTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYCAATKYSSDYDVAEDWRRGVCGDMDYWGKGTLVTVSSGGGGSGGGGS GGGGSGGGGSEVQLLESSGGGLVQPGETLRLSCTASGFTFDDSMGWYRQAPGNECELVSIISSDGMTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYCAATKYSSDYDVAEDWRRGVCGDMDYWGKGTLVTVSS SEQ ID NO:42: EVQLLESGGGLVQPGGSLRLSCTASGFTSGGSDMGWYRQAPGNECDLVSYISSDGSTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYYCAATDYGLGPPPSSTGQCYGMDYWGKGTLVTVSSGGGGSGGGGS GGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCTASGFTSGGSDMGWYRQAPGNECDLVSYISSDGSTYYADSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYYCAATDYGLGPPPSSTGQCYGMDYWGKGTLVTVSS
[0164] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.
Claims
1. An anti-TSLP nanobody, characterized in that the CDR regions, which are the complementarity determining regions of the VHH chain in said nanobody, consist of CDR1 as shown in SEQ ID NO: 14, CDR2 as shown in SEQ ID NO: 15, and CDR3 as shown in SEQ ID NO:
16.
2. The anti-TSLP Nanobody according to claim 1, characterized in that the VHH chain of said anti-TSLP Nanobody further comprises a framework region FR, said framework region FR being one or more selected from the group consisting of: (1) FR1 represented by SEQ ID NO: 17: FR2 represented by SEQ ID NO: 18, FR3 represented by SEQ ID NO: 19, and FR4 represented by SEQ ID NO: 20; (2) FR1 represented by sequence number 23, FR2 represented by sequence number 18, FR3 represented by sequence number 19, and FR4 represented by sequence number 24.
3. The anti-TSLP nanobody according to claim 1, characterized in that the amino acid sequence of the VHH chain of said anti-TSLP nanobody is selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 25, or a combination thereof.
4. An anti-TSLP antibody, characterized in that it comprises an anti-TSLP nanobody according to claim 1, which is an antibody against a TSLP epitope.
5. An anti-TSLP antibody, characterized in that it comprises one or more anti-TSLP nanobodies according to claim 1.
6. The antibody of claim 4 or 5, wherein the antibody comprises a monomeric, bivalent and / or multivalent antibody.
7. A polynucleotide encoding a protein selected from the group consisting of the anti-TSLP nanobody according to claim 1, the anti-TSLP antibody according to claim 4 or the anti-TSLP antibody according to claim 5.
8. An expression vector comprising the polynucleotide according to claim 7.
9. A host cell comprising the expression vector according to claim 8.
10. 1. A method for producing an anti-TSLP Nanobody, characterized in that the method comprises the steps of: (a) culturing the host cell of claim 9 under conditions suitable for the production of Nanobodies. obtaining a culture comprising said anti-TSLP Nanobody; (b) isolating or recovering said anti-TSLP Nanobody from said culture; and (c) purifying and / or modifying the anti-TSLP Nanobody obtained in step (b).
11. An immunoconjugate characterized in that it comprises: (a) an anti-TSLP nanobody according to claim 1, an anti-TSLP antibody according to claim 4 or an anti-TSLP antibody according to claim 5; and (b) a conjugate moiety selected from the group consisting of a detectable marker, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a gold nanoparticle / nanorod, a magnetic nanoparticle, a viral coat protein or a VLP, or a combination thereof.
12. A multispecific antibody, characterized in that it comprises an anti-TSLP nanobody according to claim 1, an anti-TSLP antibody according to claim 4 or an anti-TSLP antibody according to claim 5.
13. A recombinant protein characterized in that it comprises: (i) an anti-TSLP nanobody according to claim 1, an anti-TSLP antibody according to claim 4 or an anti-TSLP antibody according to claim 5; and (ii) A tag sequence to aid in expression and / or purification.
14. A pharmaceutical composition comprising: (i) an anti-TSLP nanobody according to claim 1, an anti-TSLP antibody according to claim 4 or an anti-TSLP antibody according to claim 5; and (ii) A pharma- ceutically acceptable carrier.
15. Use of an anti-TSLP antibody according to claim 1, an anti-TSLP antibody according to claim 4 or an anti-TSLP antibody according to claim 5, characterized in that the use is for (a) the manufacture of a drug for preventing and / or treating a disease associated with TSLP, and / or (b) the manufacture of a reagent, detection plate or kit for detecting TSLP.
16. 1. A method for detecting TSLP protein in a sample, comprising the steps of: (1) contacting a sample with an anti-TSLP nanobody according to claim 1, an anti-TSLP antibody according to claim 4 or an anti-TSLP antibody according to claim 5; (2) detecting the formation of an antigen-antibody complex, where the formation of the complex indicates the presence of TSLP protein in the sample.
17. A detection reagent for TSLP protein, comprising: (i) an anti-TSLP nanobody according to claim 1, an anti-TSLP antibody according to claim 4 or an anti-TSLP antibody according to claim 5; and (ii) A vector that is permissive for detection.
18. A kit for detecting a TSLP protein, comprising the immunoconjugate of claim 7 and an instruction manual.
19. Use of the immunoconjugate according to claim 11 for the manufacture of an imaging agent for detecting TSLP protein in the body.
Citation Information
Patent Citations
TSLP-binding protein
JP2018509153A
